Genotoxic hazard of radiopharmaceuticals in humans: Chemical and radiation aspects coupled to microdosing

European Journal of Clinical Pharmacology

Volumn 63, Issue 7, 2007, Pages 641-645

  Lundqvist, H ^a   Antoni, G ^b   Langstrom B ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Uppsala Imanet AB   (Sweden)

Author keywords

Genotoxicity; Microdosing; Radiopharmaceuticals

Indexed keywords

RADIOPHARMACEUTICAL AGENT;

ARTICLE; CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GENOTOXICITY; HAZARD; MICRODOSIMETRY; PRIORITY JOURNAL; RADIATION; RADIOACTIVITY;

CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MUTAGENICITY TESTS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; RADIATION INJURIES; RADIATION, IONIZING; RADIOISOTOPES; RADIOPHARMACEUTICALS; RISK ASSESSMENT;

EID: 34250342208     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0304-6     Document Type: Article

References (15)

1. Bergström M, Grahnén A, Långström B (2003) Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 59:357-366
2. EMEA (2004) Position Paper on non-clinical safety studies to support clinical trials with a single microdose. CPMP/swp/2599/02/Rev1
3. FDA. Guidance for industry, investigators, and reviewers exploratory IND studies. http://www.fda.gov/cder/guidance/index.htm
4. National Council of Radiation Protection (NCRP) (2001) Report no. 136 Evaluation of the linear-nonthreshold dose-response model for ionizing radiation
5. International Commission on Radiological Protection (ICRP) (2005) Committee 1 task group report: C1 foundation document (FD-C-1). Biological and epidemiological information on health risks attributable to ionising radiation: a summary of judgments for the purposes of radiological protection of humans. Draft 21 April 2005
6. Scientific and Organizing Committee (1991) Overview, early indicators of non-genotoxic carcinogenesis. Mutat Res 248:213
7. Gold LS, Slone TH, Ames BN (1998) What do animal cancer tests tell us about human cancer risk. Overview of analyses of the carcinogenic potency database. Drug Metab Rev 30(2):359-404
8. Tran NL, Locke PA, Burke TA (2000) Chemical and radiation environmental risk management: differences, commonalities, and challenges. Risk Anal 20(2):163-172
9. European Medicines Agency (2004) Guideline on the limits of genotoxic impurities.. CPMP/SWP/5199/02
10. Muller L, Mauthe RJ, Riley CM, Andino MM, Antonis DD, Beels C, DeGeorge J, De Knaep AG, Ellison D, Fagerland JA, Frank R, Fritschel B, Galloway S, Harpur E, Humfrey CD, Jacks AS, Jagota N, Mackinnon J, Mohan G, Ness DK, O'Donovan MR, Smith MD, Vudathala G, Yotti L (2006) A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul Toxicol Pharmacol 44(3):198-211
11. Kroes R, Kleiner J, Renwick A (2005) The threshold of toxicological concern concept in risk management. Toxicol Sci 86:226-230
12. 11C-carbamoyl compounds. J Org Chem 67:3687-3692
13. 18F]-FPT) for PET. J Label Compd Radiopharm 49:1079-1088
14. 11C-methionine of DNA strand break in mammalian cells. Eur J Nucl Med 11:166-170
15. Pouget JP, Mather SJ (2001) General aspects of the cellular response to low- and high-LET radiation. Eur J Nucl Med 28:541-561